Seeking Alpha
 

Teva Pharmaceutical Industries Limited (TEVA)

- NYSE
  • Thu, Apr. 30, 8:15 AM
    • Teva Pharmaceutical Industries (NYSE:TEVA) Q1 results ($M): Total Revenues: 4,982 (-0.4%); Generic Medicine: 2,621 (+9.3%); Specialty Medicine: 1,956 (-7.5%); Net Income: 446 (-40.1%); EPS: 1.36 (+56.3%); CF Ops: 1,354 (+50.8%).
    • Key product sales: Copaxone: 924 (-13.6%); Treanda: 157 (-12.8%); Women's Health: 129 (+4.0%); ProAir: 124 (+8.8%); Azilect: 107 (-6.1%); Qvar: 98 (+38.0%); Nuvigil: 85 (-15.8%).
    • 2015 Guidance: Non-GAAP EPS: $5.05 - 5.35 from $5.00 - 5.30.
    | 5 Comments
  • Thu, Apr. 30, 7:05 AM
    • Teva Pharmaceutical (NYSE:TEVA): Q1 EPS of $1.36 beats by $0.11.
    • Revenue of $4.98B (-0.4% Y/Y) beats by $140M.
    • Shares -0.19% PM.
    • Press Release
    | 2 Comments
  • Wed, Apr. 29, 3:34 PM
    • Before the open (consensus views):
    • Sanofi (SNY -1%), Revenues of $39B.
    • Celgene (CELG -0.1%), EPS of $1.06 on revenues of $2.1B.
    • AmerisourceBergen (ABC -1.2%), EPS of $1.19 on revenues of $32.3B.
    • Teva Pharmaceutical Ind. (TEVA +1.1%), EPS of $1.25 on revenues of $4.8B.
    • Shire plc (SHPG -0.6%), EPS of $2.59 on revenues of $1.5B.
    • After the close:
    • Gilead Sciences (GILD -1.3%), EPS of $2.32 on revenues of $6.9B.
    • Biomarin Pharmaceuticals (BMRN -0.2%), loss per share of ($0.53) on revenues of $203M.
    | 2 Comments
  • Thu, Feb. 5, 7:58 AM
    • Teva Pharmaceutical Industries (NYSE:TEVA) Q4 results ($M): Total Revenues: 5,168 (-4.8%); Generic Medicine: 2,469 (-7.9%); Specialty Medicine: 2,243 (+1.3%); Other: 456 (-14.9%); U.S.: 2,808 (+0.8%); Europe: 1,387 (-13.3%); ROW: 973 (-6.8%).
    • COGS: 2,279 (-10.1%); R&D Expense: 379 (-7.8%); SG&A Expense: 1,006 (-11.1%); Net Income: 687 (+80.8%); EPS: 0.80 (+77.8%); CF Ops: 1,752 (+114.7%); Quick Assets: 2,226 (+114.5%).
    • Gross Profit: 2,889 (-0.2%); COGS: 44.1% (-5.6%); Gross Margin: 55.9% (+4.9%); Operating Earnings: 1,504 (+11.3%); Operating Earnings Yield: 29.1% (+17.0%); Net Earnings Yield: 13.3% (+90.0%).
    • Key Product Sales: Copaxone: 1,121 (-1.8%); Azilect: 108 (+10.2%); Nuvigil: 105 (+38.2%); Treanda: 226 (+27.7%); ProAir: 120 (+5.3%); Qvar: 77 (-13.5%); Women's Health: 115 (-9.4%).
    | 3 Comments
  • Thu, Feb. 5, 7:03 AM
    • Teva Pharmaceutical (NYSE:TEVA): Q4 EPS of $1.31 in-line.
    • Revenue of $5.17B (-4.8% Y/Y) beats by $10M.
    • Shares +0.14% PM.
    • Press Release
    | Comment!
  • Thu, Jan. 15, 1:53 PM
    • Teva Pharmaceutical Industries (TEVA +1.4%) will report Q4 and full-year results on February 5 before the open. The conference call will begin at 8:00 am ET.
    • Consensus views for Q4 and 2014 are EPS of $1.31 and $5.07 on revenues of $5.2B and $20.3B, respectively.
    | Comment!
  • Dec. 11, 2014, 7:45 AM
    • Teva Pharmaceutical Industries (NYSE:TEVA) provides its outlook for 2015 (versus most recent guidance for 2014):
    • Net Revenues: $19.0B - 19.4B vs. $20B - 20.3B; Gross Profit: 59.5 - 61.5%; Operating Income: $5.7B - 5.9B vs. $5.65B - 5.75B; EPS: $5.00 - 5.30 vs. $5.00 - 5.10; CF Ops: $4.3B - 4.7B.
    • Generics revenues: $9.1B - 9.5B; Generics Profit: $2.4B - 2.6B; Specialty revenues: 7.9B - 8.3B; Specialty profit: $4.1B - 4.4B.
    • Copaxone: $3.5B - 3.7B; Azilect: $350M - 400M; Nuvigil: $300M - 330M; Treanda: $670M - 750M; ProAir family: $470M - 580M; Qvar family: $310M - 380M.
    • Guidance assumes the entry of two generic competitors to Copaxone in the U.S. beginning in September. Earlier entry could reduce operating income by $30M - 50M per month. Generic Pulmicort will face additional generic competition in the first half which will decrease revenues $400M - 500M and decrease operating profit by $100M - 200M.
    • Share buybacks should be $1.0B - 1.2B.
    • Shares are off a fraction premarket on average volume.
    | 1 Comment
  • Oct. 30, 2014, 2:55 PM
    • Teva Pharmaceutical Industries (TEVA +3.7%) Q3 results: Revenues: $5,058M (unch); Generic Medicine: $2,432M (-2.3%); Speciality Medicine: $2,176M (+5.1%); Gross Profit: $2,809M (+6.8%); Operating Income: $1,112M (+38.8%); Net Income: $876M (+23.2%); EPS: $1.02 (+21.4%); Quick Assets: $1,473M (+41.9%); CF Ops: $1,424M (+220.7%).
    • Product sales: Copaxone: $1,107M (+5.2%), Treanda: $180M (-2.2%), ProAir: $111M (-0.9%), Women's Health: $137M (+2.2%).
    • 2014 Guidance: Net revenues: $20B - 20.3B from $19.9B - 20.8B; Operating Income: $5.65B - 5.75B from $5.35B - 5.65B; EPS: $5.00 - 5.10 from $4.80 - 5.10.
    | Comment!
  • Oct. 30, 2014, 7:07 AM
    • Teva Pharmaceutical (NYSE:TEVA): Q3 EPS of $1.32 beats by $0.09.
    • Revenue of $5.06B (flat Y/Y) misses by $30M.
    • Press Release
    | Comment!
  • Oct. 6, 2014, 3:47 PM
    • Teva Pharmaceutical Industries (TEVA -2.6%) will report Q3 results on October 30 before the open. The conference call will begin at 7:00 am ET.
    • Consensus view is EPS of $1.22 on revenues of $5.08B.
    | Comment!
  • Jul. 31, 2014, 7:49 AM
    • Teva Pharmaceutical Industries (NYSE:TEVA) Q2 results: Total Revenues: $5,045M (+2.5%), Generic Medicine: $2,515M (+4.3%), Specialty Medicine: $2,027M (-1.2%); Operating Income: $1,094M (+14.8%); Net Income: $745M (-26.8%); EPS: $0.87 (-27.5%); CF Ops: $1,053M (+20.3%).
    • Product sales: Copaxone: $939M (-12.2%), Treanda: $190M (+7.3%), ProAir: $133M (+15.7%), Women's Health: $128M (+19.6%).
    • 2014 Guidance: no update provided.
    | Comment!
  • Jul. 31, 2014, 7:05 AM
    • Teva Pharmaceutical (NYSE:TEVA): Q2 EPS of $1.23 beats by $0.02.
    • Revenue of $5.04B (+2.4% Y/Y) misses by $40M.
    • Press Release
    | Comment!
  • May 1, 2014, 7:14 AM
    • Teva (TEVA) net income +18% to $744M.
    • On track to achieve 30,000 patients on Copaxone 40mg/mL in the U.S by end of May and 40,000 by end of year. Regular Copaxone is due to lose its patent protection this month.
    • Generic medicines +3% to $2.3B, U.S. +17% to $1B. Generic medicine segment profitability +31%.
    • Declares dividend of 1.21 shekels a share (34.7 cents). The record date will be May 20 and the payment date June 2. Tax will be withheld at a rate of 15%.
    • Reaffirms FY guidance.
    • Shares +0.6%. (PR)
    • Previous
    | Comment!
  • May 1, 2014, 7:02 AM
    • Teva Pharmaceutical (TEVA): Q1 EPS of $1.22 beats by $0.01.
    • Revenue of $5B (+2.0% Y/Y) misses by $110M.
    • Press Release
    | Comment!
  • Feb. 6, 2014, 7:39 AM
    • Teva (TEVA) net profit rises to $380M from $320M.
    • The 4.8% increase in revenue was primarily attributable to higher sales of generic medicines in the U.S., specialty medicines globally and OTC products. The rise was partially offset by a decrease in generics sales outside the U.S., mostly in Japan due to the weaker yen, and API sales to third parties.
    • Revenue breakdown: total generics +1% to $2.7B; specialty medicines +5% to $2.2B. Copaxone +8% to $1.1B.
    • Teve reaffirms its 2014 outlook.
    • Declares 2013 dividend of 1.21 shekels ($0.34) a share, +5% from Q3. The record date will be February 24, and the payment date March 10. Tax will be withheld at a rate of 15%.  (PR)
    • Previous
    | Comment!
  • Feb. 6, 2014, 7:02 AM
    • Teva Pharmaceutical Industries Limited (TEVA): Q4 EPS of $1.42 beats by $0.02.
    • Revenue of $5.45B (+4.8% Y/Y) beats by $430M.
    • Press Release
    | Comment!
Visit Seeking Alpha's
TEVA vs. ETF Alternatives
Company Description
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.
Sector: Healthcare
Country: Israel